Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357 in 2011. In 2022, Puma in-licensed global research and development and commercial rights to alisertib, a
Basic Information
- Category: Pharmaceutical Manufacturers
- Founded: 2010
- Headquarters: Los Angeles, CA
- Website: pumabiotechnology.com
Documented Facts
- Phone: 424-248-6500 (No linked source recorded for this statement.)
- Email: medinfo@pumabiotechnology.com (No linked source recorded for this statement.)
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: DE (No linked source recorded for this statement.)
- Stock ticker: PBYI (Nasdaq) (No linked source recorded for this statement.)
Evidence and Sources
- Puma Biotechnology — Official Site (official)
- PUMA BIOTECHNOLOGY, INC. — SEC EDGAR (reference)
Citation Guidance
Explore Pharmaceutical Manufacturers profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Puma Biotechnology.
- Canonical profile: https://brandsource.ai/brands/puma-biotechnology
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/puma-biotechnology/json-ld
- Citation profile API: https://brandsource.ai/api/brands/puma-biotechnology/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (90/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-28T03:57:49.940Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357 in 2011. In 2022, Puma in-licensed global research and development and commercial rights to alisertib, a
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 5 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.